CTOs on the Move


 
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.nymox.com
  • Heights Plaza 777 Terrace Avenue
    Hasbrouck Heights, NJ USA 07604
  • Phone: 800.936.9669

Executives

Name Title Contact Details

Funding

Nymox raised $16.3M on 04/12/2018

Similar Companies

Allegro Medical

Allegro Medical is a Mesa, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Haworth Cleaners

Haworth Cleaners is a Haworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sava

Sava vets the vast world of cannabis and hand-picks the highest quality topicals, tinctures, vapes, edibles, oils, CBD, and flower for delivery in the SF Bay Area.

Westmed Ambulance

Westmed Ambulance is a Baldwin Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.